Clinical Trials
Uterine Fibroids Drug Pipeline Analysis 2024: By Clinical Trial Phase: Late-Stage Products (Phase III and Phase IV), Mid-Stage Products (Phase II), Early-Stage Products (Phase I), Preclinical and Discovery Stage Products; By Drug Class: Gonadotropin-Releasing Hormone (GnRH) Agonists, GnRH Antagonists, Selective Progesterone Receptor Modulators (SPRMs), Progestins; By Product Type; By Treatment Type; Key Players
Uterine fibroids affect approximately 80% of the global female population. Around 1 in 3 or 4 women in their reproductive age are prone to get affected by the condition. More than 50% of the affected women are asymptomatic. Abnormal uterine bleeding is one of the most common symptoms exhibited in 64% of women with fibroids.
The market is witnessing a surge in drug development and treatment alternatives. Major healthcare players and research institutions are expanding are investing in drug development, leading to several drugs in the pipeline.
Key Takeaways
- Major companies involved in the uterine fibroids drugs market include Repros Therapeutics Inc., Myovant Sciences GmbH, Bayer AG, AbbVie Inc., and Takeda Pharmaceutical Industries, Ltd, among others.
- Leading drugs currently under the drug pipeline include Progenta, Proellex, and Letrozole, among others.
- Regulatory authorities like the United States FDA and EMA play an essential role in the drug pipeline for uterine fibroids as they are offering breakthrough designations and fast-track approvals to various drugs, intended to provide effective treatment alternatives to patients.
Report Coverage
The Uterine Fibroids Drug Pipeline Report by Expert Market Research gives comprehensive insights into Uterine Fibroids drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development. The report includes the analysis of over 100 pipeline drugs and 50+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on Uterine Fibroids.
The detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration and ongoing product development activities related to Uterine Fibroids are covered.
Uterine Fibroids Drug Pipeline Outlook
Uterine fibroids (also known as leiomyomas or myomas) are small non-cancerous growths in the uterus. There are not many distinctive symptoms for uterine fibroids, however, painful periods with heavy menstrual bleeding, pelvic pain or pressure, pain during intercourse, and trouble in urination may occur in patients affected by the condition. These fibroids may vary in size or number. Fibroids are more common in women in their reproductive age and may shrink as they hit menopause. The presence of fibroids is commonly diagnosed through a routine pelvic exam. Ultrasounds, MRIs, hysterosonography, hysterosalpingography and hysteroscopy can also be used.
Treatment for uterine fibroids involves the administration of medicines, non-invasive procedures like MRI-guided focused ultrasound surgery (FUS), and minimally invasive procedures like uterine artery embolization, laparoscopic or robotic myomectomy. Medications are the most common initial treatment for the condition. Gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, selective progesterone receptor modulators (SPRMs), progestins, and anti-fibrinolytic agents are some of the drug classes used to manage the disease and reduce the size of fibroids.
Uterine Fibroids – Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of uterine fibroid drugs based on various segmentations such as:
By Phase
EMR’s pipeline assessment report covers 50+ drug analyses based on phase.
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
EMR’s pipeline assessment report covers 50+ drug analyses based on drug classes:
- Gonadotropin-Releasing Hormone (GnRH) Agonists
- GnRH Antagonists
- Selective Progesterone Receptor Modulators (SPRMs)
- Progestins
- Combined Oral Contraceptives
- Anti-fibrinolytic Agents
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Aromatase Inhibitors
By Route of Administration
EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration.
- Oral
- Parenteral
- Others
Uterine Fibroids – Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase III covers a major share of the total clinical trials conducted, with over 80 drugs in the pipeline.
Uterine Fibroids – Pipeline Assessment Segmentation, By Drug Class
The drug class categories covered under uterine fibroids pipeline analysis include gonadotropin-releasing hormone (GnRH) agonists, GnRH antagonists, combined oral contraceptives, selective progesterone receptor modulators (SPRMs), nonsteroidal anti-inflammatory drugs (NSAIDs), progestins, aromatase inhibitors and anti-fibrinolytic agents and others. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials.
Uterine Fibroids Clinical Trials Assessment – Competitive Dynamics
The EMR report for the Uterine Fibroids drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in uterine fibroids clinical trials:
- Repros Therapeutics Inc.
- Myovant Sciences GmbH
- Bayer AG
- AbbVie Inc.
- Takeda Pharmaceutical Industries, Ltd
- Others
Uterine Fibroids – Pipeline Drugs Profile
Letrozole
This drug is being evaluated for the treatment of uterine fibroid-related symptoms as a part of PLUM Study, which is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial. It is under Phase 4 of the interventional study.
Proellex
Currently, under phase 2 of a multi-centre, parallel design, randomized study, this drug is under investigation to determine its safety and efficacy for premenopausal women with symptomatic uterine fibroids. Proellex ® (Telapristone Acetate), is developed by Allergan and is administered vaginally.
Progenta (CDB-4124)
Sponsored by Repros Therapeutics Inc., Progenta is currently under early-phase evaluation for symptomatic uterine fibroids in women. The trial involves administering 3 doses of Progenta (12.5, 25, 50 mg) against the placebo.
Reasons To Buy This Report
The Uterine Fibroids Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for uterine fibroids. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities.
| Scope of the Report | Details |
| Drug Pipeline by Clinical Trial Phase |
|
| Route of Administration Oral |
|
| Drug Classes |
|
| Leading Sponsors Covered |
|
| Geographies Covered |
|
Key Questions Answered in the Uterine Fibroids – Pipeline Assessment Report
- What is the current landscape of uterine fibroids pipeline drugs?
- How many companies are developing uterine fibroid drugs?
- How many phase III and phase IV drugs are currently present in uterine fibroids pipeline drugs?
- Which companies/institutions are leading the uterine fibroids drug development?
- What is the efficacy and safety profile of uterine fibroids pipeline drugs?
- What are the opportunities and challenges present in the uterine fibroids drug pipeline landscape?
- Which company is conducting major trials for uterine fibroids drugs?
- What are the geographies covered for clinical trials in uterine fibroids?
- What are emerging trends in uterine fibroids clinical trials?
Related Reports
Global Uterine Fibroid Treatment Devices Market
Global Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Overview of Uterine Fibroids
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Uterine Fibroids
3.5 Diagnosis
3.6 Treatment
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Uterine Fibroids: Epidemiology Snapshot
5.1 Uterine Fibroids Incidence by Key Markets
5.2 Uterine Fibroids– Patients Seeking Treatment in Key Markets
6 Uterine Fibroids: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Uterine Fibroids: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Uterine Fibroids, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Uterine Fibroids Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Uterine Fibroids Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 ExAblate 2000
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Relugolix
10.2.3 Vilaprisan
10.2.4 Other Drug
11 Uterine Fibroids Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Leuprorelin
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Telapristone Acetate
11.2.3 Other Drugs
12 Uterine Fibroids Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 PRA-027
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Other Drugs
13 Uterine Fibroids Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Drug 2
13.2.3 Other Drugs
14 Uterine Fibroids, Key Drug Pipeline Companies
14.1 Repros Therapeutics Inc.
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Myovant Sciences GmbH
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Bayer AG
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 AbbVie Inc.
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Takeda Pharmaceutical Industries, Ltd
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products
*Complete list of drugs covered will be provided in the report.
The EMR team aims to provide comprehensive coverage of the Top Drugs for each Phase, considering factors such as the company's financial standing, geographic presence, and market position to ensure thorough analysis in this section.
Purchase Options
Call us
Purchase Full Report
Datasheet
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2499
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3499
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4499
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER